Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2017 - 2022)

Historic Non-Current Deffered Revenue for Denali Therapeutics (DNLI) over the last 6 years, with Q4 2022 value amounting to $479000.0.

  • Denali Therapeutics' Non-Current Deffered Revenue fell 8590.35% to $479000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $479000.0, marking a year-over-year decrease of 8590.35%. This contributed to the annual value of $479000.0 for FY2022, which is 8590.35% down from last year.
  • As of Q4 2022, Denali Therapeutics' Non-Current Deffered Revenue stood at $479000.0, which was down 8590.35% from $3.4 million recorded in Q2 2022.
  • Over the past 5 years, Denali Therapeutics' Non-Current Deffered Revenue peaked at $57.4 million during Q4 2018, and registered a low of $479000.0 during Q4 2022.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $31.3 million (2021), whereas its average is $30.7 million.
  • As far as peak fluctuations go, Denali Therapeutics' Non-Current Deffered Revenue soared by 81118.53% in 2018, and later plummeted by 8915.14% in 2022.
  • Denali Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $57.4 million in 2018, then fell by 23.71% to $43.8 million in 2019, then crashed by 46.69% to $23.3 million in 2020, then crashed by 85.43% to $3.4 million in 2021, then tumbled by 85.9% to $479000.0 in 2022.
  • Its last three reported values are $479000.0 in Q4 2022, $3.4 million for Q2 2022, and $3.4 million during Q1 2022.